BetterLife Pharma Inc

CNSX:BETR

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. The company is headquartered in Vancouver, British Columbia and currently employs 3 full-time employees. The company went IPO on 2017-12-19. The firm is engaged in the development and commercialization of nutraceuticals and pharmaceuticals. Its products include AP-001, AP-002 and AP-003. AP-001 is a topical formulation of recombinant human Intensified high-dose intravenous interferon alpha 2b (IFNa2b) based on its Biphasix drug formulation technology. The Biphasix formulation allows stable cream formulation of IFNa2b and its delivery across the dermis/mucosa, with minimal systemic exposure. AP-001 is developed to treat human papillomavirus (HPV) induced cervical intraepithelial neoplasia (CIN). AP-002 is an organo-gallium complex whose drug substance is tris (8-quinolinolato) gallium (III). AP-002 has direct anti-tumor activity as well as direct anti-osteoclast activity. AP-003 is an IFNa2b inhalation formulation. The firm is also engaged in developing psychedelic compounds, peptides, pro-drugs and nutraceuticals.